The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer
Open accessAbstract
OBJECTIVE: Triple-negative breast cancer (TNBC) patients with truly chemosensitive disease still represent a minority among all TNBC patients. The aim of the present study is to identify microRNAs (miRNAs) that correlate with TNBC chemoresistance. METHODS: In this study, we conducted miRNAs profile comparison between triple-negative breast cancer (TNBCs) and normal breast tissues by microRNA array. Quantitative real-time PCR (qRT-PCR) was utilized to confirm the specific deregulated miRNAs change trend. We used starBase 2.1 and GOrilla to predict the potential targets of the specific miRNAs. Cells viability and apoptosis assays were employed to determine the effect of alteration of the specific miRNAs in TNBC cells on the chemosensitivity. RESULTS: We identified 11 specific deregulated miRNAs, including 5 up-regulated miRNAs (miR-155-5p, miR-21-3p, miR-181a-5p, miR-181b-5p, and miR-183-5p) and 6 down-regulated miRNAs (miR-10b-5p, miR-451a, miR-125b-5p, miR-31-5p, miR-195-5p and miR-130a-3p). Thereafter, this result was confirmed by qRT-PCR. We predicted the potential targets of the candidate miRNAs and found that they are involved in cancer-associated pathways. For the first time, we found that miR-130a-3p and miR-451a were down-regulated in TNBC. 9 of the 11 specific deregulated miRNAs were found to be associated with chemoresistance. In vitro assays, we found that up-regulation of either miR-130a-3p or miR-451a in MDA-MB-231 cells significantly changed the cells sensitivity to doxorubicin. The results suggest that TNBC chemotherapy might be affected by a cluster of miRNAs. CONCLUSION: The abnormal expression miRNAs in TNBC are mainly chemoresistance related. This might be part of reason that TNBC likely to evade from chemotherapy resulting in early relapse and high risk of death. To alter their expression status might be a potential therapeutic strategy to improve the outcome of chemotherapy for TNBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
Cited by
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
Exosome-mediated breast cancer chemoresistance via miR-155 transfer
Santos, J. C., Lima, N. D. S., Sarian, L. O., Matheu, A., Ribeiro, M. L., & Derchain, S. F. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19339-5 · Cited by 325
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
Metadata
- Authors
- Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., Chang, G., Li, X., Li, Q., Wang, S., & Wang, W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-02
- Volume
- 9
- Issue
- 5
- Pages
- e96228
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2069935020
- Cited by
- 195
- References
- 1
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0096228
- The paper
- Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., Chang, G., Li, X., Li, Q., Wang, S., & Wang, W. (2014). MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0096228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.